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Synthesis and antimicrobial evaluation of carbohydrate and polyhydroxylated 1 
non-carbohydrate fatty acid ester and ether derivatives. 2 
Aoife Smith, Patricia Nobmann, Gary Henehan, Paula Bourke, Julie Dunne* 3 
School of Food Science & Environmental Health, Dublin Institute of Technology. 4 
Cathal Brugha Street, Dublin 1, Ireland. 5 
 6 
Abstract 7 
A series of fatty acid ester and ether derivatives have been chemically synthesised 8 
based on carbohydrate and non-carbohydrate polyhydroxylated scaffolds.  The 9 
synthesised compounds, along with their corresponding fatty acid monoglyceride 10 
antimicrobials, were evaluated for antimicrobial activity against Staphylococcus 11 
aureus and Escherichia coli.  Of the derivatives synthesised several of the 12 
carbohydrate based compounds have antimicrobial efficacy comparable with 13 
commercially available antimicrobials.  The results suggest that the nature of the 14 
carbohydrate core plays a role in the efficacy of carbohydrate fatty acid derivatives as 15 
antimicrobials. 16 
 17 
 18 
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 1 
1. Introduction 2 
The antimicrobial effects of fatty acids have been well documented.1  Generally, long 3 
chain fatty acids have activity against Gram-positive bacteria while short chain fatty 4 
acids are more active against Gram-negative bacteria. Lauric acid (medium chain fatty 5 
acid) is regarded as the most active, with reported activity against both Gram-positive 6 
and Gram-negative bacteria.2  Lauric acid and gentamicin combined have been 7 
reported to show activity against MRSA.3  Lauric acid is inexpensive and therefore 8 
may be very useful for infection control in hospitals. 9 
Esterification of fatty acids with monohydric alcohols such as methanol or ethanol has 10 
been shown to reduce their antimicrobial activity.4  In contrast, esterification of fatty 11 
acids to the polyhydric alcohol glycerol increased their effectiveness.5  One of the 12 
most active of these antimicrobial derivatives is monolaurin (Lauricidin®), the 13 
glycerol monoester of lauric acid, which is used  as a key ingredient of antimicrobial 14 
food additives to inhibit the growth of undesirable microorganisms.6,7   15 
More recently, a study has shown that the corresponding ether of monolaurin, 16 
dodecylglycerol, had greater potency against Streptococcus faecium than monolaurin 17 
itself, albeit depending on the incubation conditions.8  The greater potency of 18 
dodecylglycerol was ascribed to its greater retention by the cell, and its action on 19 
specific receptors or enzymes.  20 
Another class of fatty acid derivatives which have broad applications in the food 21 
industry are carbohydrate fatty acid esters.9,10  While they are most commonly 22 
employed as surfactants, their antimicrobial properties have been documented.11  The 23 
use of carbohydrate esters is increasingly favoured since they are biodegradable, are 24 
not harmful to the environment and they are non-toxic.12   25 
 3 
The most common carbohydrate fatty acid ester utilised to date is sucrose ester.  They 1 
are commercially available and used for a variety of food applications.  Kato and 2 
Shibasaki  (1975) showed that the sucrose ester of lauric acid had potent antimicrobial 3 
activity against certain Gram-positive bacteria and fungi.  They further showed that, 4 
in contrast to findings with glycerides, the diester of sucrose was more active, than the 5 
monoester.  Of the diesters tested, sucrose dicaprylate showed the highest activity.13   6 
Other oligosaccharide fatty acid esters, including maltose and maltotriose, have been 7 
synthesised.  These sugar esters were shown to inhibit the growth of Streptococcus 8 
sobrinus, and are therefore potentially of significant value in the development of oral-9 
hygiene products.14  One study investigating the effect of carbohydrate monoesters 10 
reported that among those synthesised, galactose laurate, fructose laurate and the 11 
reducing 6-O-lauroylmannose showed the highest inhibitory effect against 12 
Streptococcus mutans, while other analogs of hexose laurates showed no activity.15  13 
This finding strongly suggests that the carbohydrate moiety can markedly affect the 14 
antimicrobial activity of the fatty acid and therefore further investigation is merited.   15 
Recent work in the area of carbohydrate fatty acid esters has focused on establishing 16 
an effective regioselective, enzyme catalysed, synthesis of sugar derivatives for use as 17 
surfactants for industrial applications,16,17,18,19,20 however relatively few studies have 18 
examined  role of the carbohydrate in antimicrobial activity. 14,21,22   19 
This study is concerned with the synthesis of carbohydrate and polyhydroxylated non-20 
carbohydrate fatty acid derivatives for evaluation as antibacterial agents, with a view 21 
to examining the effect of variation of the hydrophilic moiety on antimicrobial 22 
activity. Therefore, we designed chemical syntheses to investigate the effects of 23 
carbohydrate versus non-carbohydrate hydrophilic cores, the number of fatty acids 24 
attached to the hydrophilic core, the monosaccharide core itself (and the anomeric 25 
 4 
configuration with respect to glucopyranoside), the glycoconjugate linkage and the 1 
length of fatty acid chain on antimicrobial activity.   2 
A quantitative assay for antimicrobial activity was used to allow comparisons between 3 
compounds and all were measured relative to the free fatty acids and monolaurin as 4 
reference compounds.   5 
Enzymatic synthesis of novel sugar fatty acid esters has been widely employed and 6 
can be highly regioselective, although for some carbohydrates minor regiomeric 7 
isomers may be obtained. For this study, we have developed a chemical route to allow 8 
us synthesise a number of pure, regio-defined, monosaccharide mono fatty acid esters 9 
(Scheme 1).  We have also developed a route to the corresponding ether derivatives 10 
(Scheme 2).  In order to establish whether a second fatty acid conjugated to a 11 
monosaccharide would improve antimicrobial activity, a route was developed to 12 
synthesise a di-laurate derivative (Scheme 3).  Furthermore, to investigate whether the 13 
structure and therefore the synthesis, could be simplified and retain activity, non-14 
carbohydrate hydroxylated esters based on a pentaerythritol core were synthesised by 15 
a straightforward esterification (Scheme 4).  16 
2. Results and Discussion 17 
2.1 Synthesis 18 
A designed chemical route to obtain mono-ester 19 
sugars is shown in Scheme 1 and is based on the following carbohydrate starting 20 
materials: 1a methyl α-D-glucopyranoside, 1b methyl β-D-glucopyranoside, 1c methyl 21 
α-D-mannopyranoside and 1d methyl α-D-galactopyranoside.  The synthesis 22 
commenced with the selective protection of the primary hydroxyl of sugars 1a-d with 23 
a triisopropylsilyl (TIPS) group.  The silyl derivatives were then fully protected with 24 
benzyl groups to give 2a-d.  The removal of the TIPS group by tetrabutylammonium 25 
 5 
fluoride in THF allowed for the esterification of the free 6-OH position with either 1 
lauroyl chloride to yield 3a-d or octanoyl chloride to yield 5a.  Removal of the benzyl 2 
groups by catalytic hydrogenation led to the unprotected carbohydrate esters 4a-d and 3 
6a respectively. 4 
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Scheme 1 Reagents and Conditions: (i) DMF anhydr., TIPSCl, imidazole, rt. (ii) DMF anhydr., NaH, 6 
BnBr, rt. (iii) THF anhydr., 0 oC, TBAF, rt. (iv) Pyr anhydr., DMAP, Lauroyl Cl, rt. (v) EtOH, Pd-C, 7 
H2. (vi) Pyr anhydr., DMAP, Octanoyl Cl, rt. 8 
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Table 1 Percentage yields of compounds 2a-d, 3a-d, 4a-d, 5a and 6a. 5 
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 6 
Synthesis of the ether derivatives also commenced with the protection of the primary 7 
hydroxyl with a triisopropylsilyl group (Scheme 2).  The sugars were then fully 8 
protected using paramethoxybenzyl chloride (PMB), to yield 7a-b.  Removal of the 9 
TIPS group gave the free primary hydroxyl.  Next, the lauric ether group was attached 10 
using dodecanyl chloride to give the fully protected ether derivatives 8a-b.  Finally 11 
 7 
oxidative cleavage of the PMB groups with CAN gave the mono-dodecanyl sugars 1 
9a-b. 2 
 3 
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Scheme 2 Reagents and Conditions: (i) DMF anhydr., TIPSCl, imidazole, rt. (ii) DMF anhydr., THF 5 
anhydr., 0 oC, NaH, PMBCl, TBAI, rt. (iii) THF anhydr., 0 oC, TBAF, rt. (iv) DMF anhydr., dodecanyl 6 
chloride, 0 oC, NaH, rt. (v) MeCN:H2O 3:1, CAN, rt. 7 
 8 
Table 2 Percentage yields of compounds 7a-b, 8a-b and 9a-b. 9 
Carbohydrate 
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 10 
The method used to synthesise di-lauroyl derivative 12a is shown in Scheme 3.  The 4 11 
and 6-OH positions of methyl α-D-glucopyranoside 1a were protected with a 12 
benzylidene group using benzaldehyde dimethylacetal.  The remaining free OH’s 13 
 8 
were then converted to benzyl ethers to give 10a.  Removal of the benzylidene acetal 1 
using catalytic TsOH in MeOH then enabled the esterification of the 4 and 6-OH to 2 
give 11a.  Finally, removal of the benzyl groups by catalytic hydrogenation gave the 3 
diester derivative 12a. 4 
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Scheme 3. Reagents and Conditions: (i) pTSA, PhCH(OMe)2, MeCN anhydr., rt. (ii) DMF anhydr., 6 
NaH, BnBr, rt. (95% yield over 2 steps) (iii) MeOH, TsOH.  (iv) Pyr anhydr., DMAP, Lauroyl Cl, rt. 7 
(38% yield over 2 steps) (v) EtOH, Pd/, H2. (75% yield) 8 
 9 
Direct esterification of pentaerythritol 13 using lauroyl chloride and DMAP in 10 
pyridine, yielded the non-sugar derivatives 14 and 15, shown in Scheme 4. 11 
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+
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Scheme 4. Reagents and Conditions: (i) Pyr anhydr., DMAP, Lauroyl Cl, rt. (14 14%, 15 29%) 13 
 14 
2.2 Antimicrobial activity of fatty acid derivatives 15 
Two non-carbohydrate polyhydroxylated fatty acid ester derivatives, six carbohydrate 16 
fatty acid ester derivatives and two carbohydrate long chain alkyl ether derivatives, 17 
 9 
together with their corresponding polyhydric alcohols, fatty acids and monoglycerides 1 
as controls, were tested against a Gram-positive bacteria, Staphylococcus aureus, and 2 
a Gram-negative bacteria, Escherichia coli, to assess their antimicrobial activity.  The 3 
efficacy of the derivatives and controls were compared using Minimum Inhibitory 4 
Concentration values (MIC), which was defined as the lowest concentration of 5 
compound that showed no increase in cell growth for all the replicates compared to a 6 
negative control after 18 hours. 7 
The polyhydric alcohols (carbohydrates and pentaerythritol) showed no antimicrobial 8 
activity or growth promoting effects for the microorganisms under the conditions used 9 
(results not shown). 10 
Table 3 MIC values of Fatty Acid Derivatives and Controls 11 
Compound S. aureus 
ATCC 25923 
E. coli 
ATCC 25922 
Lauric acid 
Monolaurin 
Caprylic acid 
Monocaprylin 
0.63 mM 
0.04 mM 
5 mM 
2.5 mM 
10 mM 
20 mM 
12.5 mM 
6.25 mM 
Methyl 6-O-lauroyl-α-D-
glucopyranoside (4a) 
Methyl 6-O-lauroyl-β-D-
glucopyranoside (4b) 
Methyl 6-O-octanoyl-α-D-
glucopyranoside (6a) 
Methyl 6-O-dodecanyl-α-D-
glucopyranoside (9a) 
Methyl 6-O-dodecanyl-β-D-
glucopyranoside (9b) 
Methyl 4,6-di-O-lauroyl-α-D-
glucopyranoside (12a) 
0.31 mM 
 
0.04 mM 
 
2.5 mM 
 
0.04 mM 
 
2.5 mM 
 
ND* 
20 mM 
 
20 mM 
 
12.5 mM 
 
20 mM 
 
20 mM 
 
ND 
Methyl 6-O-lauroyl-α-D-
mannopyranoside (4c) 
0.04 mM 20 mM 
Methyl 6-O-lauroyl-α-D-
galactopyranoside (4d) 
>10 mM >20 mM 
Mono lauroyl pentaerythritol (14) 
Di lauroyl pentaerythritol (15) 
>10 mM 
ND 
>20 mM 
ND 
* Not determined due to insolubility 12 
 10 
The data in Table 3 show that the monoglycerides monolaurin and monocaprylin, had 1 
greater activity compared to the free fatty acids lauric acid and caprylic acid against S. 2 
aureus.  Of the monoglycerides and free fatty acids tested, monolaurin had the lowest 3 
MIC values for S. aureus, with a value of 0.04 mM compared to a value of 0.63 mM 4 
for lauric acid.  Furthermore, monocaprylin showed MIC values of 2.5 mM against S. 5 
aureus compared to the value of 5.0 mM for caprylic acid.  With respect to E. coli, 6 
monolaurin showed less inhibitory effect than lauric acid with values of 20 mM and 7 
10 mM respectively.  In contrast, monocaprylin showed activity against E. coli at 8 
concentrations of 6.25 mM compared with caprylic acid value of 12.5 mM. 9 
All fatty acid derivatives showed greater antimicrobial activity against S. aureus than 10 
E. coli.   11 
Among the sugar fatty acid esters and the sugar alkyl ethers prepared, methyl 6-O-12 
dodecanyl-α-D-glucopyranoside 9a, methyl 6-O-lauroyl-α-D-mannopyranoside 4c and 13 
methyl 6-O-lauroyl-β-D-glucopyranoside 4b showed the best inhibitory effects for S. 14 
aureus, with MIC values of 0.04 mM.  The next derivative in order of efficacy was 15 
methyl 6-O-lauroyl-α-D-glucopyranoside 4a, with a value of 0.31 mM.  Methyl 6-O-16 
octanoyl-α-D-glucopyranoside 6a was comparable to monocaprylin against S. aureus 17 
with values of 2.5 mM.  This compound was also more active than any of the lauric 18 
acid derivatives against E. coli.  Methyl 6-O-dodecanyl-β-D-glucopyranoside 9b gave 19 
similar results to 6a for S. aureus with values of 2.5 mM.  The galactopyranoside ester 20 
derivative 4d and the mono-lauroyl pentaerythritol 14, were the least active 21 
compounds tested, both with comparatively negligible MIC values of >10 mM for S. 22 
aureus and >20mM for E. coli. 23 
The di-substituted methyl 4,6-di-O-lauroyl-α-D-glucopyranoside 12a did not show 24 
any activity comparable with either the monoglycerides or indeed the mono-25 
 11 
substituted sugar derivatives.  This was attributed to poor solubility in water, as was 1 
the case for the di-substituted non-sugar compound di-lauroyl pentaerythritol 15.  2 
 3 
 4 
 5 
2.3 Discussion 6 
In this present study, we have evaluated the effect of polyhydroxylated fatty acid 7 
derivatives as inhibitors of a Gram-positive (S. aureus) and a Gram-negative (E. coli) 8 
microorganism of concern to the food and healthcare industries.  Several of the 9 
synthesised compounds have antimicrobial efficacy comparable with commercially 10 
available antimicrobials against S. aureus.  11 
We studied the effect of carbohydrate versus non-carbohydrate hydrophilic cores 12 
(carbohydrate and pentaerythritol laurates), the degree of substitution (monoester and 13 
diester), the monosaccharide core (glucopyranoside, mannopyranoside and 14 
galactopyranoside), the anomeric configuration (α and β glucopyranoside), the type of 15 
fatty acid carbohydrate linkage (ester and ether), and the length of fatty acid chain 16 
(lauric and caprylic) on antimicrobial activity.   17 
As with the monoglycerides and free fatty acids, all of the fatty acid derivatives that 18 
were found to be active showed greater antimicrobial activity against the S. aureus 19 
than E. coli.  20 
The non-carbohydrate pentaerythritol monoester 14, which has the same number of 21 
free hydroxyl groups as the carbohydrate monoester derivatives, showed negligible 22 
activity against both microorganisms tested, indicating that the carbohydrate itself 23 
could play an important role in the antimicrobial activity of these compounds. 24 
 12 
The degree of substitution of these derivatives was also shown to be crucial as both 1 
the non-sugar pentaerythritol diester 15 and the carbohydrate methyl α-D-2 
glucopyranoside diester 12a were much less soluble in water than the monoesters.  As 3 
a consequence, no antimicrobial activity results for these compounds could be 4 
obtained. 5 
With regard to the influence of different sugar cores, the results showed that the lauric 6 
ester derivative of methyl α-D-mannopyranoside 4c and methyl β-D-glucopyranoside 7 
4b, showed higher activity than any other ester derivatives against S. aureus, 8 
supporting the observation that the nature of the carbohydrate is involved in the 9 
antimicrobial efficacy of the derivatives.  This conclusion is consistent with results of 10 
an earlier study by Watanabe et al.15 11 
Further evidence for this is noted in the results for the lauric ester anomers of methyl 12 
glucopyranoside 4a and 4b.  A difference was noted when these compounds were 13 
tested against S. aureus with the beta configuration showing higher activity.  The 14 
lauric ether anomers of methyl glucopyranoside 9a and 9b also showed a marked 15 
difference in activity when tested against S. aureus, with the alpha configuration 16 
showing a much higher activity.     17 
In addition, the difference in activity between the ester and ether conjugates of the 18 
same carbohydrate showed that for the methyl α-D-glucopyranoside derivatives, the 19 
ether derivative 9a was more active than the ester 4a, however for methyl β-D-20 
glucopyranoside, the ester 4b was more active than the ether 9b.  These results 21 
indicate that, in combination with other factors, the nature of the bond conjugating the 22 
fatty acid to the carbohydrate could play some role in antimicrobial activity. 23 
The importance of the chain length of the fatty acid ester was investigated using both 24 
lauric and caprylic derivatives.  The lauric ester derivative 4a showed much higher 25 
 13 
activity against S. aureus compared to the corresponding caprylic ester derivative 6a.  1 
Conversely, the caprylic ester derivative 6a showed higher activity against E. coli, 2 
compared with the lauric derivative 4a.  This trend was also observed for the 3 
monoglyceride controls and is in accordance with general trends observed for medium 4 
and short chain fatty acids.2 5 
In conclusion, these results suggest that the nature of the carbohydrate core plays a 6 
role in the efficacy of carbohydrate fatty acid derivatives as antimicrobials, and 7 
therefore further optimisation may be possible.  However, to confirm the trends 8 
outlined with respect to the importance of the carbohydrate moiety and the role of the 9 
nature of the glycoconjugate bond, further studies are warranted using a wider range 10 
of Gram-positive and Gram-negative microorganisms, which would allow for 11 
evaluation of potential species and strain effects.   12 
3. Experimental 13 
3.1 Synthesis 14 
3.1.1 General methods 15 
All air and moisture-sensitive reactions were performed under an inert nitrogen 16 
atmosphere.  All reactions performed under a hydrogen atmosphere were performed 17 
in a Parr Hydrogenator Apparatus.  Anhydrous DMF, THF, Pyridine and MeCN were 18 
purchased from Sigma Aldrich.  TLC was performed on aluminium sheets precoated 19 
with Silica Gel 60 (HF254, Fluka) and spots visualised by UV and charring with 20 
H2SO4-EtOH (1:20).  Flash Column Chromatography was carried out with Silica Gel 21 
60 (0.040-0.630 mm, E. Merck) and using stepwise solvent polarity gradient 22 
correlated with TLC mobility.  Chromatography solvents used were EtOAc (Riedel-23 
deHaen), MeOH (Riedel-deHaen) and petroleum ether (b.p. 40-60 oC, Fluka).  Optical 24 
rotations were determined with an AA-% Series Optical Activity Ltd Polarimeter.  25 
 14 
NMR spectra were recorded with Varian Inova 300 and Varian NMRAS 400 1 
spectrometers.  Chemical shifts are reported relative to internal Me4Si in CDCl3 (δ 2 
0.0) for 1H and CDCl3 (δ 77.0) for 13C.  Coupling constants are reported in hertz.  3 
FTIR spectra were recorded with a Nicolet FT-IR 5DXB infrared spectrometer, 4 
samples were prepared in a KBr matrix.  Low resolution mass spectra were measured 5 
on a Quatromicro tandem quadropole mass spectrometer.  Methyl-α-D-6 
glucopyranoside, methyl-β-D-glucopyranoside, methyl-α-D-mannopyranoside, 7 
methyl-α-D-galactopyranoside, pentaerythritol, 1-chlorododecane, lauroyl chloride 8 
and octanoyl chloride were purchased from Sigma Aldrich. 9 
3.1.2  Methyl 2,3,4-tri-O-benzyl-6-O-triisopropylsilyl-α-D-glucopyranoside (2a) 10 
A solution of 1a (5 g, 25 mmol) in DMF anhydrous (120 mL) was treated with 11 
triisopropylsilyl chloride (15 mL, 75 mmol) and imidazole (5 g, 75 mmol) and 12 
allowed to stir at room temperature for 24 h.  The crude TIPS protected intermediate 13 
was then concentrated in vacuo and dissolved in EtOAc.  It was washed with 10% 14 
HCl, water, followed by sat. aq. NaHCO3, and finally sat. aq. NaCl.  It was then dried 15 
over anhydrous MgSO4, and concentrated under reduced pressure.23  The crude 16 
product was dissolved in DMF anhydrous (50 mL) and cooled to 0 oC.  NaH (5 g, 125 17 
mmol) was added portion wise, BnBr (9 mL, 75 mmol) was added and the mixture 18 
was allowed to warm to room temperature and stir for 24 h.  MeOH (50 mL) was 19 
added to quench the mixture which was stirred for 1 h.  The fully protected sugar was 20 
then concentrated in vacuo and dissolved in EtOAc.  The solution was washed with 21 
water, dried over anhydrous MgSO4, and concentrated under diminished pressure.24  22 
The resulting residue was purified by chromatography (petroleum ether-EtOAc) to 23 
give 2a (13.2 g, 85%); [α]D 10.7º (c 0.07, CHCl3); FTIR (KBr): 2923, 1733, 1498, 24 
1455, 909, 884, 791, 695 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.36-7.27 (ms, 15H, 25 
 15 
aromatic H), 4.91, (AB d, 2H, J 11.0, OCH2Ph),  4.78, (AB d, 2H, J 11.0, OCH2Ph),  1 
4.74 (AB d, 2H, J 12.0, OCH2Ph), 4.61 (d, 1H, J1,2 3.5, H-1), 3.99 (apt t, 1H, J2,3 9.5, 2 
J3,4 9.5, H-3), 3.84 (d, 2H, J5,6 4.5, H-6a,6b), 3.64 (m, 1H, H-5), 3.55-3.49 3 
(overlapping signals, 2H, H-2,4), 3.37 (s, 3H, OCH3), 1.10-1.02 (ms, 18H, each TIPS 4 
CH3), 0.88 (m, 3H, each TIPS CH); 13C NMR (CDCl3): δ 139.1, 138.7, 138.5 (each s, 5 
each aromatic C), 128.65, 128.63, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8 (each d, 6 
each aromatic CH), 98.0 (d, C-1), 82.5, 80.5, 78.1, 76.1 (each d), 76.1, 75.3, 73.6 7 
(each t, each CH2Ph), 62.9 (t, C-6), 55.0 (q, OCH3), 18.3, 18.2 (each q, each TIPS 8 
CH3), 12.2 (each d, each TIPS CH); LRMS: Found, 643.3; required, 643.9; [M + 9 
Na]+. 10 
3.1.3  Methyl 2,3,4-tri-O-benzyl-6-O-triisopropylsilyl-β-D-glucopyranoside (2b) 11 
Treatment of 1b (4.5 g, 23.17 mmol) as described for 1a gave 2b (8.7 g, 80%); [α]D 12 
23º (c 0.01, CHCl3); FTIR (KBr): 2863, 1730, 1497, 1454, 1399, 1277, 882, 802, 751, 13 
697. cm-1; 1H NMR (400 MHz, CDCl3): δ 7.37-7.28 (ms, 15H, aromatic H), 4.90, 14 
4.88, 4.83 (each AB d, 6H, J 11.0, OCH2Ph), 4.30 (d, 1H, J1,2 7.5, H-1), 4.00-3.90 15 
(overlapping signals, 3H, H-5,6), 3.66 (m, 1H, H-3), 3.53 (s, 3H, OCH3), 3.41 (m, 1H, 16 
H-2), 3.34 (m, 1H, H-4), 1.26-1.05 (ms, 21H, TIPS); 13C NMR (CDCl3): δ 138.98, 17 
138.92, 138.7 (each s, each aromatic C), 128.69, 128.65, 128.62, 128.5, 128.3, 128.2, 18 
128.0, 127.9, 127.8 (each d, each aromatic CH), 104.7 (d, C-1), 84.9, 82.9, 77.8, 76.2 19 
(each d), 76.0, 75.3, 75.0 (each t, each CH2Ph), 62.7 (t, C-6), 56.9 (q, OCH3), 18.3, 20 
18.2 (each q, each TIPS CH3), 12.3 (d, TIPS CH); LRMS: Found, 643.3 required, 21 
643.9 [M + Na]+. 22 
3.1.4 Methyl 2,3,4-tri-O-benzyl-6-O-triisopropylsilyl-α-D-mannopyranoside (2c) 23 
Treatment of 1c (4 g, 20 mmol) as described for 1a gave 2c (6.5 g, 51%); [α]D 25.5º (c 24 
0.05, CHCl3); FTIR (KBr): 3056, 2864, 1496, 1363, 1324, 970, 882, 790, 734, 696 25 
 16 
cm-1; 1H NMR (400 MHz, CDCl3): δ 7.38-7.24 (multiple signals, 15H, each aromatic 1 
H), 4.79 (AB d, 2H, J 11.0, OCH2Ph), 4.72 (AB d, 2H, J 12.0, OCH2Ph), 4.71-4.64 2 
(overlapping signals, 3H, OCH2Ph, H-1), 3.95 (dd, 1H, J2,3 2.0, J3,4 11.0, H-3), 3.93-3 
3.87 (overlapping signals, 3H, H-4,6a,6b), 3.76 (dd, 1H, J1,2 2.5, H-2), 3.59 (dd, 1H, J  4 
5.5, J  7.0, H-5), 3.31 (s, 3H, OMe), 1.12-1.04 (multiple signals, 21H, TIPS); 13C 5 
NMR (CDCl3): δ 138.68, 138.61, 138.4 (each s, each aromatic C), 128.3, 128.2, 6 
127.9, 127.67, 128.63, 127.5, 127.4 (each d, each aromatic CH), 98.5 (d, C-1), 80.3, 7 
76.7, 74.9, 73.3 (each d), 75.1, 72.5, 72.1 (each t, each CH2Ph), 63.2 (t, C-6), 54.4 (q, 8 
OMe), 18.0, 17.9 (each q, each TIPS CH3), 12.3 (each d, each TIPS CH2); LRMS: 9 
Found, 638.5 required, 638.9; [M + H2O]+. 10 
3.1.5 Methyl 2,3,4-tri-O-benzyl-6-O-triisopropylsilyl-α-D-galactopyranoside 11 
(2d) 12 
Treatment of 1d (4.0 g, 20.0 mmol) as described for 1a gave 2d (6.4 g, 50%); [α]D 13 
20.6º (c 0.07, CHCl3); FTIR (KBr): 3030, 2865, 1496, 1454, 1350, 1194, 1054, 882, 14 
793, 734, 696 cm-1; 1H NMR (400 MHz, CDCl3): δ; 7.41-7.22 (multiple signals, 15H, 15 
each aromatic H), 4.82 (AB d, 2H, J 12.0, OCH2Ph), 4.71 (AB d, 2H, J 11.5, 16 
OCH2Ph), 4.77 (AB d, 2H, J 12.0, OCH2Ph), 4.68 (d, 1H, J1,2 3.5, H-1), 4.04 (dd, 1H, 17 
J2,3 10.0, H-2), 3.95-3.92 (overlapping signals, 2H, H-3,5), 3.74-3.64 (overlapping 18 
signals, 3H, H-4,6), 3.36 (s, 3H, OMe), 1.12-0.86 (multiple signals, 21H, TIPS); 13C 19 
NMR (CDCl3): δ 137.9, 137.7, 137.5 (each s, each aromatic C), 127.33, 127.28, 20 
127.22, 127.15, 127.06, 126.62, 126.48, 126.45 (each d, each aromatic CH), 97.6 (d, 21 
C-1), 78.1, 75.4, 74.0, 70.1 (each d), 73.7, 72.5, 72.2 (each t, each CH2Ph), 61.4 (t, C-22 
6), 54.1 (q, OMe), 16.94, 16.93 (each q, each TIPS CH3), 10.8 (each d, each TIPS 23 
CH2); LRMS: Found, 638.5 required, 638.9; [M + H2O]+. 24 
3.1.6 Methyl 2,3,4-tri-O-benzyl-6-O-lauroyl-α-D-glucopyranoside (3a) 25 
 17 
Compound 2a (3.0 g, 4.8 mmol) was dissolved in THF anhydrous (80 mL) and was 1 
cooled to 0 oC.  Tetrabutylammonium fluoride (1 g, 4 mmol) was added and the 2 
solution was allowed to warm to room temperature and stir for 1 h.25  It was then 3 
concentrated in vacuo and approximately 1 mmol of the resulting 6-OH residue was 4 
dissolved in pyridine anhydrous (25 mL).  4-Dimethylaminopyridine and lauroyl 5 
chloride (0.29 mL, 1.22 mmol) were added and the solution was allowed to stir at 6 
room temperature for 24 h.26  It was then concentrated under reduced pressure and the 7 
resulting benzylated ester derivative was purified by chromatography (petroleum 8 
ether-EtOAc) to give 3a (0.47 g, 72%); [α]D 7.5º (c 0.02, CHCl3); FTIR (KBr): 2924, 9 
2853, 1738, 1603, 1502, 1454, 1249, 1072 cm1; 1H NMR (400 MHz, CDCl3): δ 7.35-10 
7.26 (ms, 15H, aromatic H),  4.92, (AB d, 2H,  J 10.5, OCH2Ph),  4.72, (AB d, 2H,  J 11 
10.5, OCH2Ph),  4.64  (AB d, 2H, J 12.0, OCH2Ph), 4.59 (d, 1H, J1,2 3.5, H-1), 4.27 12 
(d, 2H, J5,6 3.5, H-6a,6b), 4.01 (apt t, 1H, J2,3 9.5, J3,4 9.0,  H-3), 3.82 (d apt t, 1H, J4,5 13 
10.0, H-5), 3.53 (dd, 1H, H-2), 3.48 (apt t, 1H, H-4) 3.37 (s, 3H, OCH3), 2.35 (m, 2H, 14 
aliphatic OCOCH2C10H21), 1.61 (m, 2H, aliphatic OCOCH2CH2C9H19), 1.28-1.24 15 
(ms, 16H, aliphatic OCOC2H4C8H16CH3), 0.87 (m, 3H, aliphatic OCOC10H20CH3); 16 
13C NMR (CDCl3): δ 171.1 (s, C=O), 138.6, 138.1, 137.9 (each s, each aromatic C), 17 
128.5, 128.48, 128.46, 128.1, 128.03, 127.98, 127.90, 127.7 (each d, each aromatic 18 
CH), 98.0 (d, C-1), 88.0, 79.9, 77.6, 68.6 (each d), 75.8, 75.1, 73.4 (each t, each 19 
CH2Ph), 60.4 (t, C-6), 55.2 (q, OCH3), 34.2, 31.9, 29.8, 29.6, 29.5, 29.3, 29.2, 24.9, 20 
22.7, 21.1 (each t, each aliphatic CH2), 14.2 (q, aliphatic CH3); LRMS: Found, 21 
669.39; required, 669.85; [M + Na]+; Anal. Calcd. for C40H54O7: C, 74.27; H, 8.41. 22 
Found: C, 73.98; H, 8.30.  23 
3.1.7 Methyl 2,3,4-tri-O-benzyl-6-O-lauroyl-β-D-glucopyranoside (3b) 24 
 18 
Treatment of 2b (3.0 g, 4.8 mmol) as described for 2a gave  3b (2.2 g, 70%); [α]D 8.3º 1 
(c 0.03, CHCl3); FTIR (KBr): 2924, 2853, 1739, 1497, 1454, 1356, 1151, 1070, 735 2 
cm-1; 1H NMR (400 MHz, CDCl3): δ 7.36-7.24 (ms, 15H, aromatic H), 4.87, 4.84, 3 
4.72 (each AB d, 6H, J 10.5, OCH2Ph), 4.37 (d, 2H, J5,6 11.5, H-6a,6b), 4.31 (d, 1H, 4 
J1,2 8.0, H-1), 4.25 (m, 1H, H-5), 3.67 (apt t, 1H, J2,3 8.5, J3,4 8.5, H-3), 3.56 (s, 3H, 5 
OCH3), 3.54 (m, 1H, H-4), 3.43 (dd, 1H, H-2), 2.32 (m, 2H, aliphatic 6 
OCOCH2C10H21), 1.62 (m, 2H, aliphatic OCOCH2CH2C9H19), 1.26-1.24 (ms, 16H, 7 
each aliphatic OCOC2H4C8H16CH3), 0.88 (t, 3H, J 6.0, J 7.0, aliphatic 8 
OCOC11H23CH3); 13C NMR (CDCl3): δ 173.6 (s, C=O), 138.43, 138.42, 137.8 (each 9 
s, each aromatic C), 128.8, 128.5, 128.4, 128.38, 128.34, 128.26, 128.11, 128.07, 10 
127.97, 127.92, 127.8, 127.7, 127.69, 127.64, 127.5 (each d, each aromatic CH), 11 
104.7 (d, C-1), 84.6, 82.3, 77.6, 72.9 (each d), 75.7, 75.1, 74.8 (each t, each OCH2Ph), 12 
62.9 (t, C-6), 57.1 (q, OCH3), 34.2, 31.9, 29.6, 29.5, 29.3, 29.2, 29.1, 24.9, 24.7, 22.6 13 
(each t, each aliphatic CH2), 14.1 (q, aliphatic CH3); LRMS: Found, 669.2 required, 14 
669.9 [M + Na]+; Anal. Calcd. for C40H54O7: C, 74.27; H, 8.41. Found: C, 73.91; H, 15 
8.79.  16 
3.1.8 Methyl 2,3,4-tri-O-benzyl-6-O-lauroyl-α-D-mannopyranoside (3c) 17 
Treatment of 2c (6.2 g, 10.0 mmol) as described for 2a gave  3c (4.1 g, 64%); [α]D 18 
23.3º (c 0.04, CHCl3); FTIR (KBr): 3031, 2924, 2853, 1737, 1496, 1454, 1362, 1066, 19 
1027, 970, 909, 735, 697 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.38-7.25 (multiple 20 
signals, 15H, each aromatic H), 4.77 (AB d, 2H, J 10.5, OCH2Ph), 4.74 (d, 1H, J1,2 21 
2.0, H-1), 4.72 (AB d, 2H, J 12.5, OCH2Ph), 4.61 (s, 2H, OCH2Ph), 4.38 (dd, 1H, J5,6a 22 
2.5, J6a,6b 12.0, H-6a), 4.33 (dd, 1H, J5,6b 5.0, H-6b), 3.94-3.88 (overlapping signals, 23 
2H, H-3,4), 3.78 (dd, 1H, J2,3 2.5, H-2), 3.76 (m, 1H, H-5), 3.31 (s, 3H, OMe), 2.32 (t, 24 
2H, J 7.5, J 7.5, aliphatic OCOCH2C10H21), 1.61 (m, 2H, aliphatic 25 
 19 
OCOCH2CH2C9H19), 1.31-1.54 (ms, 16H, aliphatic OCOC2H4C8H16CH3), 0.91-0.86 1 
(m, 3H, aliphatic OCOC10H20CH3); 13C NMR (CDCl3): δ 173.7, (s, C=O), 138.32, 2 
138.21, 138.17 (each s, each aromatic C), 128.4., 128.38, 128.33, 128.05. 127.90, 3 
127.76, 127.63, 127.23 (each d, each aromatic CH), 98.9 (d, C-1), 75.2, 74.6, 74.4, 4 
69.9 (each d), 80.1, 72.6, 72.1 (each t, each CH2Ph), 63.3 (t, C-6), 54.8 (q, OCH3), 5 
34.2, 33.9, 31.9, 29.61, 29.48, 29.44, 29.33, 29.27, 29.17, 29.07, 24.9, 24.7, 23.8, 6 
22.7, 21.1 (each t, each aliphatic CH2), 14.1 (q, aliphatic CH3); LRMS: Found, 664.6 7 
required, 664.9; [M + H2O]+; Anal. Calcd. for C40H54O7: C, 74.27; H, 8.41. Found: C, 8 
74.35; H, 8.25.  9 
3.1.9 Methyl 2,3,4-tri-O-benzyl-6-O-lauroyl-α-D-galactopyranoside (3d) 10 
Treatment of 2d (5.7 g, 9.2 mmol) as described for 2a gave 3d (3.6 g, 60%); [α]D 11 
27.8º (c 0.09, CHCl3); FTIR (KBr): 3030, 2924, 2853, 1738, 1496, 1454, 1350, 1099, 12 
1049, 735, 696 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.41-7.23 (multiple signals, 15H, 13 
each aromatic H), 4.83 (AB d, 2H, J 12.0, OCH2Ph), 4.81 (AB d, 2H, J 11.5, 14 
OCH2Ph), 4.77 (AB d, 2H, J 12.0, OCH2Ph), 4.68 (d, 1H, J1,2 3.5, H-1),  4.16 (dd, 1H, 15 
J 7.5, J 11.5, H-4), 4.07-4.03 (overlapping signals, 2H, H-2,5), 3.94 (dd, 1H, J 3.0, J 16 
10.0 H-6a), 3.86-3.84 (overlapping signals, 2H, H-3,6b),  3.35 (s, 3H, OMe), 2.23 (m, 17 
2H, aliphatic OCOCH2C10H21), 1.57 (m, 2H, aliphatic OCOCH2CH2C9H19), 1.31-1.18 18 
(ms, 16H, aliphatic OCOC2H4C8H16CH3), 0.88 (t, 3H, J 6.5, J 7.0, aliphatic 19 
OCOC10H20CH3); 13C NMR (CDCl3): δ 173.4 (s, C=O), 138.7, 138.4, 138.2 (each s, 20 
each aromatic C), 128.42, 128.36, 128.32, 128.11, 127.90, 127.75, 127.59, 127.51, 21 
127.21 (each d, each aromatic CH), 98.7 (d, C-1), 78.9, 76.3, 74.9, 68.4 (each d), 74.6, 22 
73.63, 73.54 (each t, each CH2Ph), 63.3 (t, C-6), 55.3 (q, OCH3), 34.1, 33.8, 31.9, 23 
29.359, 29.45, 29.32, 29.26, 29.12, 24.9, 24.8, 22.7 (each t, each aliphatic CH2), 14.1 24 
 20 
(q, aliphatic CH3); LRMS: Found, 664.6 required, 664.9; [M + H2O]+; Anal. Calcd. 1 
for C40H54O7: C, 74.27; H, 8.41. Found: C, 74.67; H, 8.68.  2 
3.1.10 Methyl 6-O-lauroyl-α-D-glucopyranoside (4a) 3 
Compound 3a (0.34 g, 0.2 mmol) was dissolved in EtOH (1 mL) and Pd-C (0.1 g) 4 
was added.  The mixture was allowed to shake under hydrogen atmosphere of 2 psi 5 
until all protecting groups had been removed, as shown by TLC, to yield 4a.  The 6 
suspension was filtered and concentrated in vacuo.27  (0.17 g, 86%); [α]D 19º (c 0.02, 7 
CHCl3); FTIR (KBr): 3734, 3445, 2955, 2924, 2850, 2359, 2341, 1728. cm-1; 1H 8 
NMR (400 MHz, CDCl3): δ 4.75 (d, 1H, J1,2 3.5, H-1), 4.33 (m, 2H, H-6), 3.75-3.73 9 
(overlapping signals, 2H, H-3,5), 3.35 (apt t, 1H, J3,4 9.5, J4,5  9.5, H-4), 3.54 (dd, 1H, 10 
J2,3 9.5, H-2), 3.41 (s, 3H, OMe), 2.35 (t, 2H, J 7.5, aliphatic OCOCH2C10H21), 1.63 11 
(m, 2H, aliphatic OCOCH2CH2C9H19), 1.38-1.23 (ms, 16H, aliphatic 12 
OCOC2H4C8H16CH3), 0.88 (t, 3H, J 7.0, aliphatic OCOC10H20CH3); 13C NMR 13 
(CDCl3): δ 174.2 (s, C=O), 99.4 (d, C-1), 74.1, 71.9, 70.4, 69.8 (each d), 63.5 (t, C-6), 14 
55.2 (q, OCH3), 34.2, 31.9, 29.66, 29.64, 29.5, 29.4, 29.3, 29.2, 24.9, 22.7 (each t, 15 
each aliphatic CH2), 14.1 (q, aliphatic CH3); LRMS: Found, 399.3 required, 399.5; [M 16 
+ Na]+; Anal. Calcd. for C19H36O7: C, 60.61; H, 9.64. Found: C, 60.69; H, 9.83.  17 
3.1.11 Methyl 6-O-lauroyl-β-D-glucopyranoside (4b) 18 
Treatment of 3b (2.0 g, 3.0 mmol) as described for 3a gave  4b (0.86 g, 75%); [α]D –19 
25.5º (c 0.05, CHCl3); FTIR (KBr): 3421, 2921, 1744, 1703, 1016 cm-1; 1H NMR (400 20 
MHz, CDCl3): δ 4.40 (d, 1H, J1,2 11.5, H-1), 4.28 (dd, 1H, J2,3 6.0, H-2), 4.21 (d, 2H, 21 
J5,6 7.5, H-6), 3.54 (s, 3H, OCH3), 3.49 (m, 1H, H-3), 3.39-3.31 (overlapping signals, 22 
2H, H-4,5), 2.34 (m, 2H, aliphatic OCOCH2C10H21), 2.02 (s, 3H, OH), 1.62 (m, 2H, 23 
aliphatic OCOCH2CH2C9H19), 1.28-1.26 (ms, 16H, aliphatic OCOC2H4C8H16CH3), 24 
0.88 (t, 3H, J 6.5, aliphatic OCOC10H20CH3); 13C NMR (CDCl3): δ 174.2 (s, C=O), 25 
 21 
103.6 (d, C-1), 76.5, 73.9, 73.4, 70.3 (each d), 63.6 (t, C-6), 57.0 (q, OCH3), 34.2, 1 
31.9, 29.61, 29.60, 29.5, 29.3, 29.2, 29.1, 24.9, 22.7 (each t, each aliphatic CH2), 14.1 2 
(q, aliphatic CH3); LRMS: Found, 399.1 required, 399.5 [M + Na]+; Anal. Calcd. for 3 
C19H36O7: C, 60.61; H, 9.64. Found: C, 60.25; H, 9.91.  4 
3.1.12 Methyl 6-O-lauroyl-α-D-mannopyranoside (4c) 5 
Treatment of 3c (3.3 g, 5.0 mmol) as described for 3a gave 4c ( 1.4 g, 75%); [α]D 6 
33.3º (c 0.01, CHCl3); FTIR (KBr): 3421, 2923, 1736, 1466, 1197, 1057 cm-1; 1H 7 
NMR (400 MHz, CDCl3): δ 4.70 (s, 1H, H-1), 4.45 (br s, 1H, OH), 4.36 (d, 2H, J 4.0, 8 
H-6), 3.96-3.92 (overlapping signals, 2H, OH, H-2), 3.78 (dd, 1H, J2,3 2.5, J3,4 9.0, H-9 
3), 3.71 (m, 1H, H-5), 3.62 (apt t, 1H, J4,5 9.5, H-4) 3.36 (s, 3H, OMe), 2.35 (t, 2H, J 10 
7.5, J 7.5, aliphatic OCOCH2C10H21), 1.61 (m, 2H, aliphatic OCOCH2CH2C9H19), 11 
1.29-1.25 (ms, 16H, aliphatic OCOC2H4C8H16CH3), 0.88 (t, 3H, J 6.5, J 7.0, aliphatic 12 
OCOC10H20CH3); ); 13C NMR (CDCl3): δ 174.7 (s, C=O), 100.9 (d, C-1), 71.5, 70.5, 13 
70.4, 67.7 (each d), 63.9 (t, C-6),  54.9 (q, OCH3), 34.2, 31.9, 29.7, 29.6, 29.5, 29.4, 14 
29.36, 29.34, 29.19, 24.9, 22.7 (each t, each aliphatic CH2), 14.1 (q, aliphatic CH3); 15 
LRMS: Found, 377.3 required, 377.5; [M + H]+; Anal. Calcd. for C19H36O7: C, 60.61; 16 
H, 9.64. Found: C, 60.71; H, 9.53. 17 
3.1.13 Methyl 6-O-lauroyl-α-D-galactopyranoside (4d) 18 
Treatment of 3d (2.8 g, 4.4 mmol) as described for 3a gave 4d ( 1.43 g, 86%); [α]D 19 
56.25º (c 0.01, CHCl3); FTIR (KBr): 3250, 2918, 1741, 1467, 1194, 1025cm-1; 1H 20 
NMR (400 MHz, CDCl3): δ 4.63 (apt t, 1H, J 6.5, J 5.0, OH-3), 4.57 (d, 1H, J 6.5, 21 
OH-2),  4.55 (d, 1H, J1,2 3.5, H-1), 4.13 (dd, 1H, J5,6a 8.0, J6a,6b 11.5, H-6a), 4.07 (dd, 22 
1H, J5,6b 4.0, H-6b), 3.75 (dd, 1H, H-5), 3.68 (apt t, 1H, J3,4 3.5, J4,5  3.0, H-4), 3.58 23 
(ddd, 1H, J2,3 10.0, J2,OH 16.5, H-2), 3.52 (m, 1H, H-3), 3.24 (s, 3H, OMe), 2.28 (t, 24 
2H, J 7.5, aliphatic OCOCH2C10H21), 1.63 (t, 2H, J 7.0, aliphatic 25 
 22 
OCOCH2CH2C9H19), 1.28-1.23 (ms, 16H, aliphatic OCOC2H4C8H16CH3), 0.85 (t, 3H, 1 
J 7.0, aliphatic OCOC10H20CH3); 13C NMR (CDCl3): δ 178.2 (s, C=O), 104.8 (d, C-2 
1), 74.9, 74.1, 73.7, 73.1 (each d), 68.8 (t, C-6), 59.8 (q, OCH3), 38.9, 36.5, 34.24, 3 
34.10, 33.97, 33.93, 33.75, 29.5, 27.3, (each t, each aliphatic CH2), 18.9 (q, aliphatic 4 
CH3); LRMS: Found, 399.3 required, 399.5; [M + Na]+; Anal. Calcd. for C19H36O7: C, 5 
60.61; H, 9.64. Found: C, 60.60; H, 9.88. 6 
3.1.14 Methyl 2,3,4-tri-O-benzyl-6-O-octanoyl-α-D-glucopyranoside (5a) 7 
Compound 2a (5.0 g, 8.5 mmol) was dissolved in THF anhydrous (150 mL) and was 8 
cooled to 0 oC.  Tetrabutylammonium fluoride (2.2 g, 8.5 mmol) was added and the 9 
solution was warmed to room temperature and stirred for 1 h.25  The mixture was then 10 
concentrated in vacuo and the resulting 6-OH residue was dissolved in pyridine 11 
anhydrous (100 mL).  4-Dimethylaminopyridine and octanoyl chloride (2.9 mL, 17 12 
mmol) was added and the mixture was stirred at room temperature for 24 h.26  The 13 
solution was then concentrated under reduced pressure and purified by 14 
chromatography (petroleum ether-EtOAc) to give 5a (3.9 g, 63%); [α]D 20.8º (c 0.07, 15 
CHCl3); FTIR (KBr): 2927, 1738, 1497, 1454, 1360, 1163, 1093, 738, 697 cm-1; 1H 16 
NMR (400 MHz, CDCl3): δ 7.37-7.26 (ms, 15H, aromatic H), 4.93, (AB d, 2H, J 17 
10.5, OCH2Ph), 4.74, (AB d, 2H, J 12.0, OCH2Ph), 4.73 (AB d, 2H, J 10.5, OCH2Ph), 18 
4.60 (d, 1H, J1,2 3.5, H-1), 4.28 (d, 2H, J5,6 3.0, H-6), 4.01 (apt t, 1H, J2,3 9.5, J3,4 9.5, 19 
H-3), 3.81 (m, 1H, H-5), 3.54 (dd, 1H, H-2), 3.48 (dd, 1H, J4,5 10.5, H-4), 3.37 (s, 3H, 20 
OCH3), 2.31 (m, 2H, aliphatic OCOCH2C6H13), 1.62 (m, 2H, aliphatic 21 
OCH2CH2C5H11), 1.30-1.05 (ms, 8H, aliphatic OC2H4C4H8CH3), 0.87 (m, 3H, 22 
aliphatic OC6H12CH3); 13C NMR (CDCl3): δ 173.8 (s, C=O), 138.8, 138.3, 138.1 23 
(each s, each aromatic C), 128.7, 128.6, 128.3, 128.29, 128.27, 128.3, 128.25, 128.20, 24 
128.1 127.9 (each d, each aromatic CH), 98.3 (d, C-1), 82.2, 80.2, 77.8, 68.9 (each d), 25 
 23 
76.1, 75.3, 73.6 (each t, each OCH2Ph), 63.1 (t, C-6), 55.4 (q, OCH3), 34.4, 31.9, 1 
29.2, 25.0, 22.8, 17.9 (each t, each aliphatic CH2), 14.3 (q, aliphatic CH3); LRMS: 2 
Found, 613.4 required, 613.7; [M + Na]+; Anal. Calcd. for C36H46O7: C, 73.19; H, 3 
7.85. Found: C, 73.25; H, 7.61 4 
3.1.15 Methyl 6-O-octanoyl-α-D-glucopyranoside (6a) 5 
Treatment of 5a (3.6 g, 6.2 mmol) as described for 3a gave  6a (1.44 g, 73%); [α]D 6 
27.9º (c 0.4, CHCl3); FTIR (KBr): 3388, 2922, 1712, 1465, 1193, 1106, 724 cm-1; 1H 7 
NMR (400 MHz, CDCl3): δ 5.82 (s, 3H, each OH), 4.76 (d, 1H, J1,2 3.5, H-1), 4.35 (d, 8 
2H, J5,6 4.0, H-6), 3.78-3.72 (overlapping signals, 2H, H-3,5), 3.54 (dd, 1H, J2,3 9.5, 9 
H-2), 3.41 (s, 3H, OCH3), 3.36 (dd, 1H, J3,4 9.5, J4.5 10.0, H-4), 2.35 (m, 2H, aliphatic 10 
COCH2C6H13)  1.64 (t, 2H, J 7.0, aliphatic COCH2CH2C5H11), 1.31-1.05 (ms, 8H, 11 
aliphatic COC2H4C4H8CH3), 0.88 (t, 3H, J 5.5, J 7.0, aliphatic COC6H12CH3); 13C 12 
NMR (CDCl3): δ 179.5 (s, C=O), 99.4 (d, C-1), 74.1, 72.0, 69.7, 70.3 (each d), 63.4 13 
(t, C-6), 55.3 (q, OCH3),  34.1, 31.7, 31.6, 29.9, 28.9, 24.8 (each t, each aliphatic 14 
CH2), 14.1 (q, aliphatic CH3); LRMS: Found, 343.1 required, 343.4; [M + Na]+; Anal. 15 
Calcd. for C15H28O7: C, 56.23; H, 8.81. Found: C, 56.47; H, 8.73.  16 
3.1.16 Methyl 2,3,4-tri-O-paramethoxybenzyl-6-O-triisopropylsilyl-α-D-17 
glucopyranoside (7a) 18 
A solution of 1a (5.0 g, 25.0 mmol) in DMF anhydrous (120 mL) was treated with 19 
triisopropylsilyl chloride (15 mL, 75 mmol) and imidazole (5 g, 75 mmol) and 20 
allowed to stir at room temperature for 24 h.  The crude TIPS protected intermediate 21 
was then concentrated in vacuo and the resulting residue dissolved in EtOAc.  It was 22 
then washed with 10% HCl, water, followed by sat. aq. NaHCO3, and finally sat. aq. 23 
NaCl, before being dried over anhydrous MgSO4, and concentrated under reduced 24 
pressure.23  The TIPS protected crude residue was then split in two and half was 25 
 24 
dissolved in DMF anhydrous (30 mL) and THF anhydrous (20 mL).  This solution 1 
was then added dropwise at 0 oC to a suspension of NaH (2.5 g, 62.5 mmol) in DMF 2 
anhydrous (10 mL) and THF anhydrous (7 mL), paramethoxybenzyl chloride (17 mL, 3 
125 mmol) and tetrabutylammonium iodide (18.5 g, 50 mmol).  This was stirred at 4 
approximately 10 oC for 30 min and then allowed to warm to room temperature and 5 
stir for 24 h.   MeOH (50 mL) was added to quench the mixture which was stirred for 6 
1 h.  The solution was then concentrated under diminished pressure and dissolved in 7 
EtOAc.  It was washed with water, dried over anhydrous MgSO4, and concentrated in 8 
vacuo.
28
  The resulting residue was purified by chromatography (petroleum ether-9 
EtOAc) to give 7a.  (5.15 g, 59%); [α]D 11.6º (c 0.05, CHCl3); FTIR (KBr): 3479, 10 
2936, 2864, 1464, 1421, 1360, 1302, 883, 820. cm-1; 1H NMR (400 MHz, CDCl3): δ 11 
7.34-6.73 (ms, 12H, aromatic H), 4.88 (AB d, 2H, J 10.5 OCH2Ph), 4.78 (d, 1H, J1,2 12 
5.0, H-1), 4.75, 4.71 (each AB d, 2H, J 12.0 OCH2Ph), 4.63 (m, 1H, H-2), 3.99 (apt t, 13 
1H, J3,4 9.0, J4,5 9.0, H-4), 3.89 (m, 2H, H6), 3.77 (m, 9H, each PhOCH3), 3.57-3.49 14 
(overlapping signals, 2H, H-3,5), 3.39 (s, 3H, OCH3), 1.28 (m, 3H, each TIPS CH), 15 
1.16-1.06 (ms, 18H, each TIPS CH3); 13C NMR (CDCl3): δ 159.6, 159.5, 159.4, 16 
131.6, 131.4, 131.0 (each s, each aromatic C), 129.99, 129.93, 129.8, 114.13, 114.08, 17 
113.6 (each d, each aromatic CH), 98.1 (d, C-1), 82.2, 80.2, 77.8, 72.1 (each d), 75.8, 18 
74.9, 73.2 (each t, each OCH2Ph), 63.1 (t, C-6), 55.47, 55.40, 55.36 (each q, each 19 
PhOCH3), 55.0 (q, OCH3), 18.27, 18.25 (each q, each TIPS CH3), 12.3 (d, each TIPS 20 
CH); LRMS: Found, 733.3 required, 733.9 [M + Na]+. 21 
3.1.17 Methyl 2,3,4-tri-O-paramethoxybenzyl-6-O-triisopropylsilyl-β-D-22 
glucopyranoside (7b) 23 
Treatment of 1b (4.5 g, 23.17 mmol) as described for 1a gave 7b (10.1 g, 61%); [α]D 24 
4.8º (c 0.05, CHCl3); FTIR (KBr): 2939, 1586, 1464, 883, 821, 760, 683. cm-1; 1H 25 
 25 
NMR (400 MHz, CDCl3): δ 7.30-6.84 (ms, 12H, aromatic H), 4,85, 4.80, 4.73 (each 1 
AB d, 2H, J 10.5, OCH2Ph), 4.27 (d, 1H, J1,2 7.5, H-1), 3.95 (m, 1H, H-6a), 3.87 (dd, 2 
1H, J4,5 11.0, J5,6 4.5, H-5), 3.78 (m, 9H, PhOCH3), 3.59 (m, 1H, H-3), 3.53 (s, 3H, 3 
OCH3) 3.36 (apt t, 1H, J2,3 9.0, H-2), 3.29-3.24 (overlapping signals, 2H, H-4,6b), 4 
1.10-1.04 (ms, 21H, TIPS); 13C NMR (CDCl3): δ 159.5, 159.4, 131.2, 131.1, 130.9, 5 
(each s, each aromatic C), 129.9, 129.8, 128.7, 114.1, 114.04, 114.01 (each d, each 6 
aromatic CH), 104.7 (d, C-1), 84.7, 82.6, 77.5, 76.2 (each d), 75.7, 74.9, 74.7 (each t, 7 
each OCH2PH), 62.7 (t, C-6), 56.8 (q, OCH3), 55.5 (each q, each PhOCH3), 18.3, 18.2 8 
(each q, each TIPS CH3), 12.2 (d, each TIPS CH); LRMS: Found, 733.3; required, 9 
733.9 [M + Na]+. 10 
3.1.18 Methyl 2,3,4-tri-O-paramethoxybenzyl-6-O-dodecanyl-α-D-11 
glucopyranoside (8a) 12 
Compound 7a (4.0 g, 5.5 mmol) was dissolved in THF anhydrous (100 mL) and was 13 
cooled to 0 oC.  Tetrabutylammonium fluoride (1.4 g, 5.5 mmol) was added and the 14 
solution was allowed to warm to room temperature and stir for 1 h.25  The mixture 15 
was then concentrated in vacuo, and the resulting 6-OH residue was dissolved in 16 
DMF anhydrous (100 mL).  1-chlorododecane (1.8 mL, 11 mmol) was added and the 17 
solution was cooled to 0 oC before NaH (0.11 g, 2.75 mmol) was added portion wise.  18 
The mixture was then allowed to warm to room temperature and was stirred for 24 h.  19 
MeOH (50 mL) was added to quench the solution which was stirred for 1 h.29  The 20 
crude PMB protected ether was then concentrated under diminished pressure and 21 
purified by chromatography (petroleum ether-EtOAc) to give 8a (1.89 g, 50%); [α]D –22 
8.6º (c 0.06, CHCl3); FTIR (KBr): 2924, 2854, 1613, 1586, 1464, 1359, 1301, 1248, 23 
1172, 1037, 820 cm-1; 1H NMR (400 MHz, CDCl3): δ 6.85-7.30 (ms, 12H, aromatic 24 
H), 4.92 (d, 1H, J1,2 10.5, H-1), 4.85 (AB d, 2H, J 10.5, OCH2PhOCH3), 4.74 (dd, 1H, 25 
 26 
J2,3 9.5, H-2), 4.69, (AB d, 2H, J 10.5, OCH2PhOCH3), 4.60 (AB d, 2H, J 11.5 1 
OCH2PhOCH3), 4.55 (apt t, 1H, J3,4 9.5, H-3), 3.95 (m, 1H, H-5), 3.80 (s, 9H, each 2 
PhOCH3), 3.53-3.37 (overlapping signals, 3H, H-4,6a,6b), 3.36 (s, 3H, OCH3), 1.60 3 
(m, 2H, aliphatic CH2C11H23), 1.30-1.25 (ms, 20H, aliphatic CH2C10H20CH3), 0.89 (t, 4 
3H, J 7.0, aliphatic C11H20CH3); 13C NMR (CDCl3): δ 159.6, 159.5, 159.4, 131.3, 5 
131.0, 130.6 (each s, each aromatic C), 130.0, 129.8, 129.6, 114.07, 114.05, 114.03 6 
(each d, each aromatic CH), 98.5 (d, C-1), 82.1, 79.8, 77.7, 70.2 (each d), 75.7, 74.9, 7 
73.3 (each t, each OCH2Ph), 72.0 (t, aliphatic OCH2C11H23), 69.5 (t, C-6), 55.5 (q, 8 
PhOCH3), 55.3 (s, OCH3), 32.2, 29.94, 29.91, 29.89, 29.87, 29.84, 29.7, 29.5, 28.4 9 
(each t, each aliphatic CH2), 14.4 (q, aliphatic CH3); LRMS: Found, 745.5; required, 10 
745.9; [M + Na]+; Anal. Calcd. for C43H62O9: C, 71.44; H, 8.64. Found: C, 71.09; H, 11 
8.73. 12 
3.1.19 Methyl 2,3,4-tri-O-paramethoxybenzyl-6-O-dodecanyl-β-D-13 
glucopyranoside (8b) 14 
Treatment of 7b (3.2 g, 4.5 mmol) as described for 7a gave 8b (0.55 g, 85%); [α]D 2º 15 
(c 0.01, CHCl3); FTIR (KBr): 2923, 2851, 1614, 1464.40, 1421, 1359, 1302, 1254, 16 
1173, 1072, 813 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.29-6.84 (ms, 12H, aromatic 17 
H), 4.79, 4.75, 4.67 (each AB d, 2H, J 10.5, OCH2Ph), 4.26 (d, 1H, J1,2 7.5, H-1), 18 
3.79-3.58 (overlapping signals, 2H, H-3,5), 3.79 (m, 9H, PhOCH3), 3.68 (m, 2H, H-19 
6a,6b), 3.56 (s, 3H, OCH3), 3.43-3.39 (overlapping signals, 2H, H-2,4), 1.63 (m, 2H, 20 
aliphatic OCH2C11H23), 1.29-1.24 (ms, 20H, aliphatic OCH2C10H20CH3), 0.88 (t, 3H, 21 
J 7.0, aliphatic OC11H22CH3); 13C NMR (CDCl3): δ 159.3, 159.2, 159.1, 130.9, 130.8, 22 
130.5 (each s, each aromatic C), 129.8, 129.6, 129.5, 113.8, 113.7 (each d, each 23 
aromatic CH), 104.8 (d, C-1), 84.4, 82.1, 77.7, 75.3 (each d), 74.9, 74.6, 74.4 (each t, 24 
each OCH2Ph), 71.9 (t, aliphatic CH2), 69.7 (t, C-6), 57.1 (q, OCH3), 55.3, 55.2 (each 25 
 27 
q, each PhOCH3), 31.9, 29.7, 29.68, 29.65, 29.63, 29.5, 29.4, 26.2, 22.7 (each t, each 1 
aliphatic CH2), 14.1 (q, aliphatic CH3); LRMS: Found, 745.3; required, 745.9; [M + 2 
Na]+; Anal. Calcd. for C43H62O9: C, 71.44; H, 8.64. Found: C, 71.19; H, 8.70.  3 
3.1.20  Methyl 6-O-dodecanyl-α-D-glucopyranoside (9a) 4 
Compound 8a (1.45 g, 2.0 mmol) was dissolved in a mixture of MeCN:H2O (3:1) (21 5 
mL) and cerric ammonium nitrate (8.85 g, 16.16 mmol) was added.  The solution was 6 
allowed to stir at room temperature for 24 h.30  It was then concentrated in vacuo and 7 
purified by chromatography (petroleum ether-EtOAc) to give 9a (0.53 g, 73%); [α]D 8 
78.8º (c 0.04, CHCl3); FTIR (KBr): 3416, 2919, 2851, 1467, 1372, 1128, 1043, 1019 9 
cm-1; 1H NMR (400 MHz, CDCl3): δ 4.98 (br s, 1H, OH), 4.75 (d, 1H, J1,2 3.5, H-1), 10 
4.34 (br s, 1H, OH), 4.01 (br s, 1H, OH), 3.75 (apt t, 1H, J2,3 9.5, J3,4 9.5, H-3), 3.66 11 
(m, 2H, H-6), 3.54-3.44 (overlapping signals, 3H, H-2,4,5), 3.37 (s, 3H, OCH3), 1.58 12 
(m, 2H, aliphatic CH2C11H23), 1.28-1.25 (ms, 20H, each aliphatic CH2C10H20CH3), 13 
0.88 (t, 3H, J 6.5, J 7.0, aliphatic C11H20CH3); 13C NMR (CDCl3): δ 99.7 (d, C-1), 14 
74.5, 72.3, 72.2, 71.2 (each d) 70.6 (t, aliphatic CH2), 69.5 (t, C-6), 55.4 (q, OCH3), 15 
32.1, 29.9, 29.88, 29.86, 29.83, 29.7, 29.6, 26.3, 22.9 (each t, each aliphatic CH2), 16 
14.3 (q, aliphatic CH3); LRMS: Found, 385.2; required, 385.5; [M + Na]+; Anal. 17 
Calcd. for C19H38O6: C, 62.95; H, 10.57. Found: C, 62.60; H, 10.67. 18 
3.1.21 Methyl 6-O-dodecanyl-β-D-glucopyranoside (9b) 19 
Treatment of 8b (0.44 g, 0.6 mmol) as described for 8a gave 9b (0.17 g, 76%); [α]D –20 
1º (c 0.03, CHCl3); FTIR (KBr): 3405, 2922, 2850, 1470, 1391, 1128, 1109, 1048 cm-21 
1; 1H NMR (400 MHz, CDCl3): δ 4.20 (d, 1H, J1,2 7.5, H-1), 3.89 (s, 1H, OH), 3.74 22 
(m, 2H, H-6a,6b), 3.66 (m, 1H, H-5), 3.54 (s, 3H, OCH3), 3.52-3.44 (overlapping 23 
signals, 2H, H-3,4), 3.35 (apt t, 1H, J2,3 8.0, H-2), 1.58 (m, 2H, aliphatic 24 
OCH2C11H23), 1.28-1.11 (ms, 20H, aliphatic OCH2C10H20CH3), 0.88 (t, 3H, J 6.5, J 25 
 28 
7.0, aliphatic OC11H22CH3); 13C NMR (CDCl3): δ 103.5 (d, C-1), 76.5, 74.4, 73.4, 1 
72.1, (each d), 71.6 (t, aliphatic CH2), 70.9 (t, C-6), 57.1 (q, OCH3), 31.9, 29.7, 29.66, 2 
29.65, 29.58, 29.53, 29.4, 26.0, 22.7 (each t, each aliphatic CH2), 14.1 (q, aliphatic 3 
CH3); LRMS: Found, 385.2; required, 385.5; [M + Na]+; Anal. Calcd. for C19H38O6: 4 
C, 62.95; H, 10.57. Found: C, 62.83; H, 10.36. 5 
3.1.22 Methyl 2,3-di-O-benzyl-4,6-di-O-benzylidene-α-D-glucopyranoside (10a) 6 
A solution of 1a (1.0 g, 5.2 mmol), p-toluenesulfonic acid (10 mg) and benzaldehyde 7 
dimethylacetal (1.5 mL, 10.3 mmol) in acetonitrile anhydrous (25 mL) was stirred for 8 
24 h at room temperature.  Trimethylamine (0.5 mL) was added to neutralise the 9 
solution which was then stirred for 1 h.  The product was filtered off as a white solid, 10 
washed with petroleum ether and dried.  The benzylidene protected intermediate was 11 
then dissolved in DMF anhydrous (15 mL) and the solution was cooled to 0 oC.  NaH 12 
(0.74 g, 18.4 mmol) was added slowly, followed by benzyl bromide (2.5 mL, 20 13 
mmol).  The mixture was then warmed to room temperature and stirred over night.  14 
MeOH (10 mL) was added to quench the solution which was stirred for a further 1 15 
hr.24  The mixture was then concentrated under diminished pressure and purified by 16 
chromatography (petroleum ether-EtOAc) to give 10a.  (2.0 g, 95%); [α]D 0.7º (c 0.05, 17 
CHCl3); FTIR (KBr): 3063, 3031, 1109, 1088, 735, 692 cm-1; 1H NMR (400 MHz, 18 
CDCl3): δ 7.50-7.22 (ms, 15H, each aromatic H), 5.54 (s, 1H, CHPh), 4.85 (AB d, 2H, 19 
J 4.0, OCH2Ph), 4.82 (AB d, 2H, J 12.0, OCH2Ph), 4.59 (d, 1H, J1,2 3.5, H-1), 4.26 20 
(dd, 1H, J5,6a 10.0, J6a,6b 4.5, H-6a), 4.05 (apt t, 1H, J2,3 9.0, J3,4 9.0, H-3), 3.83 (m, 21 
1H, H-5), 3.70 (apt t, 1H, J5,6b 10.5, H-6b), 3.62-3.54 (overlapping signals, 2H, H-22 
2,4), 3.39 (s, 3H, OCH3); 13C NMR (CDCl3): δ 138.7, 138.1, 137.4 (each s, each 23 
aromatic C), 128.89, 128.43, 128.29, 128.20, 128.10, 128.01, 127.90, 127.57, 126.0 24 
(each d, each aromatic CH), 101.2 (d, C-1), 99.2 (d, CHPh), 82.1, 79.2, 78.6, 62.3 25 
 29 
(each d), 75.3, 73.8 (each t), 69.1 (t, C-6), 55.3 (q, OCH3); LRMS: Found, 463.3 1 
required, 463.5; [M + H]+; Anal. Calcd. for C28H30O6: C, 72.71; H, 6.54. Found: C, 2 
72.31; H, 6.56.  3 
3.1.23 Methyl 4,6-di-O-lauroyl-α-D-glucopyranoside (12a) 4 
3.1.23.1 Methyl 2,3-di-O-benzyl-4,6-di-O-lauroyl-α-D-glucopyranoside (11a) 5 
Compound 10a (1.7 g, 3.6 mmol) was dissolved in MeOH (50 mL) and a catalytic 6 
amount of TsOH was added.  The solution was stirred at room temperature overnight, 7 
after which Et3N (2 mL) was added to quench the reaction.31  The mixture was 8 
concentrated under diminished pressure and the crude diol residue was dissolved in 9 
pyridine anhydrous (70 mL).  4-Dimethylaminopyridine and lauroyl chloride (3.3 mL, 10 
14.4 mmol) was added and the reaction was stirred at room temperature for 3 h.26  The 11 
solution was then concentrated under diminished pressure and purified by 12 
chromatography (petroleum ether-EtOAc) to give 11a.  (1.0 g, 38%); FTIR (KBr): 13 
2925, 2853, 1743, 1455, 1360, 1167, 1105, 1045, 734 cm-1; 1H NMR (400 MHz, 14 
CDCl3): δ 7.34-7.26 (multiple signal, 10H, each aromatic H), 5.01 (dd, 1H, J3,4 9.5, 15 
J4,5 10.0, H-4), 4.78 (AB d, 2H, J 11.5, OCH2Ph), 4.73 (AB d, 2H, J 12.0, 16 
OCH2Ph),4.59 (d, 1H, J1,2 3.5, H-1), 4.15 (dd, 1H, J5,6a 5.5, J6a,6b 12.5, H-6a), 4.04 17 
(dd, 1H, J5,6b 2.0, H-6b), 3.92 (apt t, 1H, J2,3 9.5, H-3), 3.87-3.82 (m, 1H, H-5), 3.59 18 
(dd, 1H, H-2), 2.36-2.27 (m, 4H,  each aliphatic OCOCH2C10H21), 1.67-1.56 (m, 4H, 19 
each aliphatic OCOCH2CH2C9H19), 1.26-1.16 (ms, 32H, each aliphatic 20 
OCOC2H4C8H16CH3), 0.88 (t, 6H, J 6.5, J 7.0, each aliphatic OCOC10H20CH3); 13C 21 
NMR (CDCl3): δ 173.6, 172.4 (each s, each C=O), 138.4, 137.9 (each s, each 22 
aromatic C), 128.51, 128.32, 128.18, 128.05. 127.69, 127.57 (each d, each aromatic 23 
CH), 98.2 (d, C-1), 79.51, 79.18, 69.5, 67.7 (each d), 75.4, 73.6 (each t, each CH2Ph), 24 
62.2 (t, C-6), 55.4 (q, OCH3), 34.15, 34.03, 33.99, 31.9, 29.62, 29.60, 29.49, 29.44, 25 
 30 
29.35, 29.34, 29.28, 29.26, 29.15, 29.13, 29.07, 24.76, 24.70, 22.69 (each t, each 1 
aliphatic CH2), 14.1 (q, aliphatic CH3). 2 
3.1.23.2 Methyl 4,6-di-O-lauroyl-α-D-glucopyranoside (12a) 3 
Compound 11a (0.84 g, 1.14 mmol) was dissolved in EtOH (2.5 mL) and Pd/C (0.3 g) 4 
was added.  The mixture was allowed to shake under hydrogen atmosphere of 2 psi 5 
until all protecting groups had been removed as shown by TLC to yield 12a.  The 6 
suspension was filtered and concentrated in vacuo.27  (0.47 g, 75%); [α]D 4.33º (c 7 
0.03, CHCl3); FTIR (KBr): 3456, 2918, 2849, 1737, 1701, 1468, 1301, 1240, 1187, 8 
1046 cm-1; 1H NMR (400 MHz, CDCl3): δ 4.87 (dd, 1H, J3,4 9.5, J4,5 10, H-4), 4.82 (d, 9 
1H, J1,2 4.0, H-1), 4.23 (dd, 1H, J5,6b 2.0, J6a,6b 12.0, H-6b), 4.12 (dd, 1H, J5,6a 2.0, H-10 
6a), 3.91 (ddd, 1H, H-5), 3.84 (apt t, 1H, J2,3 9.5, H-3), 3.64 (m, 1H, H-2), 3.44 (s, 3H, 11 
OMe), 2.37-2.32 (m, 4H, each aliphatic OCOCH2C10H21), 1.68-1.55 (m, 4H, each 12 
aliphatic OCOCH2CH2C9H19), 1.30-1.26 (multiple signals, 32 H, each aliphatic 13 
OCOC2H4C8H16CH3), 0.88 (t, 6H, J 6.5, J 7.0, each aliphatic OCOC10H20CH3); 13C 14 
NMR (CDCl3): δ 173.63, 173.58 (each s, each C=O), 99.0 (d, C-1), 72.9, 72.7, 70.3, 15 
67.7 (each d), 62.2 (t, C-6), 55.5 (q, OMe), 34.2, 34.1, 34.0, 31.9, 29.63, 29.61, 29.50, 16 
29.47, 29.45, 29.36, 29.30, 29.27, 29.14, 29.08, 24.84, 24.82, 24.70, 22.70 (each t, 17 
each aliphatic CH2), 14.1 (q, aliphatic CH3); LRMS: Found, 559.5 required, 559.8; [M 18 
+ H]+; Anal. Calcd. for C31H58O8: C, 66.63; H, 10.46. Found: C, 66.66; H, 10.79.  19 
 20 
3.1.24 General procedure for the preparation of pentaerythritol esters 21 
Pentaerythritol 13 (1.0 g, 7.3 mmol), lauroyl chloride (4.8 mL, 21 mmol) and 4-22 
dimethylaminopyridine were dissolved in pyridine anhydrous (50 mL) and stirred at 23 
50 oC for 24 h.26  The solution was then concentrated in vacuo, and the following 24 
 31 
mono-lauroyl 14 and di-lauroyl 15 products were isolated by chromatography 1 
(petroleum ether-EtOAc) a tetra-lauroyl derivative was also isolated (0.39 g, 6%): 2 
3.1.25 Mono lauroyl pentaerythritol (14) 3 
(0.33 g, 14%); FTIR (KBr): 3462, 2914, 2848, 1737, 1712, 1476, 1187, 1038, 1005 4 
cm-1; 1H NMR (400 MHz, CDCl3): δ 4.10 (s, 2H, CH2OC=O), 3.80-3.61 (overlapping 5 
signals, 9H, 3 x CH2OH, 3 x OH), 2.34 (t, 2H, J 6.0, J 7.0,  aliphatic 6 
OCOCH2C10H21), 1.61 (m, 2H, aliphatic OCOCH2CH2C9H19), 1.26 (ms, 16H, 7 
aliphatic OCOC2H4C8H16CH3), 0.88 (m, 3H, aliphatic OCOC10H20CH3); 13C NMR 8 
(CDCl3): δ 175.0 (s, C=O), 62.7, 62.4 (each t, each CH2O), 45.3 (s, C(CH2)4), 34.2, 9 
31.9, 29.59, 29.57, 29.44, 29.30, 29.23, 29.15, 24.9, 22.6 (each t, each aliphatic CH2), 10 
14.1 (q, aliphatic CH3); LRMS: Found 341.2, required 341.45 [M+Na]+; Anal. Calcd. 11 
for C17H34O5: C, 64.12; H, 10.76. Found: C, 64.08; H, 10.79.  12 
3.1.26 Di lauroyl pentaerythritol (15) 13 
(1.074 g, 29%); FTIR (KBr): 3351, 2915, 2850, 1739, 1701, 1471, 1163, 978, 719 cm-14 
1; 1H NMR (400 MHz, CDCl3): δ 4.12 (s, 4H, each CH2OC=O), 3.58 (s, 4H, each 15 
CH2OH), 3.22 (br s, 2H, each OH) 2.34 (t, 4H, J 7.5, J 7.5,  each aliphatic 16 
OCOCH2C10H21), 1.62 (t, 4H, J 6.5, J 6.5, each aliphatic OCOCH2CH2C9H19), 1.29-17 
1.26 (ms, 32H, each aliphatic OCOC2H4C8H16CH3), 0.88 (t, 6H, J 6.5, J 6.5, each 18 
aliphatic OCOC10H20CH3); 13C NMR (CDCl3): δ 174.4 (s, each C=O), 62.4 (t, each 19 
CH2O), 44.7 (s, C(CH2)4), 34.2, 31.9, 29.56, 29.29, 29.21, 29.11, 24.9, 22.6 (each t, 20 
each aliphatic CH2), 14.1 (q, each aliphatic CH3); LRMS: Found 501.5, required 21 
501.75 [M+H]+; Anal. Calcd. for C29H56O6: C, 69.56; H, 11.27. Found: C, 69.64; H, 22 
11.31.  23 
3.1.27 Tetra lauroyl pentaerythritol 24 
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(0.39 g, 6%); FTIR (KBr): 2917, 2849, 1735, 1336, 1299, 1250, 1154, 1111, 1002 cm-1 
1; 1H NMR (400 MHz, CDCl3): δ 4.11 (s, 8H, each CH2OC=O), 2.30 (t, 8H, J 7.5, J 2 
8.0,  each aliphatic OCOCH2C10H21), 1.60 (t, 8H, J 6.5, J 7.0, each aliphatic 3 
OCOCH2CH2C9H19), 1.41-1.26 (ms, 64H, each aliphatic OCOC2H4C8H16CH3), 0.88 4 
(t, 12H, J 6.5, J 7.0, each aliphatic OCOC10H20CH3); 13C NMR (CDCl3): δ 173.2 (s, 5 
each C=O), 62.1 (t, each CH2O), 41.8 (s, C(CH2)4), 34.1, 31.9, 29.59, 29.45, 29.31, 6 
29.23, 29.11, 24.8, 22.7 (each t, each aliphatic CH2), 14.1 (each q, each aliphatic 7 
CH3); LRMS: Found 888.7, required 888.36 [M+Na]+; Anal. Calcd. for C53H100O8: C, 8 
73.56; H, 11.65. Found: C, 73.60; H, 11.58.  9 
3.2 Evaluation of anti-microbial activity 10 
3.2.1  Preparation of bacterial cultures 11 
Bacteria used in this study were Staphylococcus aureus ATCC 25923 and Escherichia 12 
coli ATCC 25922.  Stock cultures were maintained in tryptic soy broth (TSB, Sharlau 13 
Chemie, Spain) supplemented with 20% glycerol at -70 °C.  Cultures were routinely 14 
grown by subculturing 100 µL of stock culture into 9 mL TSB and incubating at 35 15 
°C for 18 h.   Cultures were then maintained on tryptic soy agar (TSA, Sharlau 16 
Chemie, Spain) plates at 4 °C.  Working cultures were prepared by inoculating a loop 17 
of pure culture into TSB and incubating at 35 ºC for 18 h.  A bacterial suspension was 18 
prepared in saline solution (NaCl 0.85%, BioMérieux, France) equivalent to a 19 
McFarland standard of 0.5, using the Densimat photometer (BioMérieux, SA, France), 20 
to obtain a concentration of 1x108 cfu/mL.  This suspension was then serially diluted 21 
in TSB to obtain a working concentration of  1x106 cfu/mL. 22 
3.2.2 Anti-microbial activity assay 23 
Stock solutions (100 mmol) of test compounds and standards were prepared in sterile 24 
hydroalcoholic diluent (ethanol-distilled water, 1:1) and stored at -20 °C.  Stock 25 
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solutions were diluted in TSB to obtain initial working concentrations (10 or 20 1 
mmol).  Working test compounds and standards were serially diluted in sterile TSB to 2 
a final volume of 100 µL within the 96-well plate.  100 µL of freshly prepared 3 
inoculum of the organism under study was added to each appropriate well.  The final 4 
concentration of each microorganism in each well was approximately 5x105 cfu/mL 5 
and the concentration range of chemical compounds was from 1:2 to 1:256.  Each 6 
concentration was assayed in duplicate.  The following controls were used in the 7 
microplate assay for each organism and test compound; blank: uninoculated media 8 
without test compound to account for changes in the media during the experiment; 9 
negative control: uninoculated media containing only the test compound; positive 10 
control 1: inoculated media without compound; positive control 2: inoculated media 11 
without compound but including the corresponding sugar to evaluate any effect of the 12 
sugar alone; and positive control 3: inoculated media without compound but with the 13 
equivalent concentration of ethanol used to dissolve the test compound, thereby 14 
assessing any activity of the alcohol.  The 96-well plates were incubated at 35 °C for 15 
18 hours in a microtiterplate reader (PowerWave microplate Spectrophotometer, 16 
BioTek) and effects were monitored by measuring the optical density (OD) at 600 nm 17 
for each well every 20 minutes with 20 seconds agitation before each OD 18 
measurement.  Each experiment was replicated three times.  The MIC was defined as 19 
the lowest concentration of compound that showed no increase in OD values for all 20 
the replicates compared to the negative control after 18 hours.  Subtraction of the 21 
absorbance of the negative control eliminated interferences due to variation in the 22 
media.  23 
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